A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This was a placebo controlled, double blind, randomized phase II dose-response study to
evaluate the efficacy and safety of BF-200 ALA (containing the active ingredient 5 -
aminolevulinic acid- ALA) used with photodynamic therapy (PDT) in patients with actinic
keratosis (AK).